

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

**FORM 10-Q**

(Mark One)

**QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

For the quarterly period ended September 30, 2018

OR

**TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

For the transition period from      to

Commission file number: 001-33277

**MADRIGAL PHARMACEUTICALS, INC.**

(Exact name of registrant as specified in its charter)

**Delaware**

(State or other jurisdiction  
of incorporation or organization)

**04-3508648**

(I.R.S. Employer Identification No.)

**Four Tower Bridge**

**200 Barr Harbor Drive, Suite 400  
West Conshohocken, Pennsylvania**  
(Address of principal executive offices)

**19428**

(Zip Code)

Registrant's telephone number, including area code: **(484) 380-9263**

Former name, former address and former fiscal year, if changed since last report:

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes  No

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes  No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer

Accelerated filer

Non-accelerated filer

Smaller reporting company   
Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes  No

As of November 01, 2018, the registrant had 15,393,309 shares of common stock outstanding.

---

---

## MADRIGAL PHARMACEUTICALS, INC.

## TABLE OF CONTENTS

| <u>Item</u>                                 | <u>Description</u>  | <u>Page</u> |
|---|---|-------------|
| <b><u>Part I. Financial Information</u></b> |   |             |
| <u>Item 1.</u>                              | <u>Financial Statements (Unaudited):</u>  | 3           |
|   | <u>Condensed Consolidated Balance Sheets at September 30, 2018 and December 31, 2017</u>  | 3           |
|   | <u>Condensed Consolidated Statements of Operations for the Three Months and Nine Months Ended September 30, 2018 and 2017</u>         | 4           |
|   | <u>Condensed Consolidated Statements of Comprehensive Loss for the Three Months and Nine Months Ended September 30, 2018 and 2017</u> | 5           |
|   | <u>Condensed Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2018 and 2017</u>                          | 6           |
|   | <u>Notes to Condensed Consolidated Financial Statements</u>   | 7           |
| <u>Item 2.</u>                              | <u>Management's Discussion and Analysis of Financial Condition and Results of Operations</u>  | 15          |
| <u>Item 3.</u>                              | <u>Quantitative and Qualitative Disclosures About Market Risk</u>   | 19          |
| <u>Item 4.</u>                              | <u>Controls and Procedures</u>  | 20          |
| <b><u>Part II. Other Information</u></b>    |   |             |
| <u>Item 1.</u>                              | <u>Legal Proceedings</u>  | 21          |
| <u>Item 1A.</u>                             | <u>Risk Factors</u>   | 21          |
| <u>Item 2.</u>                              | <u>Unregistered Sales of Equity Securities and Use of Proceeds</u>  | 21          |
| <u>Item 3.</u>                              | <u>Defaults Upon Senior Securities</u>  | 21          |
| <u>Item 4.</u>                              | <u>Mine Safety Disclosures</u>  | 21          |
| <u>Item 5.</u>                              | <u>Other Information</u>  | 21          |
| <u>Item 6.</u>                              | <u>Exhibits</u>   | 21          |
|   | <u>Signatures</u>   | 23          |

## PART I - FINANCIAL INFORMATION

## Item 1. Financial Statements.

**MADRIGAL PHARMACEUTICALS, INC.**  
**CONDENSED CONSOLIDATED BALANCE SHEETS**  
(Unaudited; in thousands, except share and per share amounts)

|   | September 30,<br>2018 | December 31,<br>2017 |
|---|-----------------------|----------------------|
| <b>Assets</b>   |                       |                      |
| Current assets:   |                       |                      |
| Cash and cash equivalents   | \$ 38,046             | \$ 148,627           |
| Marketable securities   | 450,492               | 42,900               |
| Prepaid expenses and other current assets   | 767                   | 485                  |
| Total current assets  | 489,305               | 192,012              |
| Property and equipment, net   | 244                   | 301                  |
| Total assets  | \$ 489,549            | \$ 192,313           |
| <b>Liabilities and Stockholders' Equity</b>   |                       |                      |
| Current liabilities:  |                       |                      |
| Accounts payable  | \$ 1,031              | \$ 1,929             |
| Accrued expenses  | 5,611                 | 8,125                |
| Total current liabilities   | 6,642                 | 10,054               |
| Total liabilities   | 6,642                 | 10,054               |
| Stockholders' equity:   |                       |                      |
| Preferred stock, par value \$0.0001 per share authorized: 5,000,000 shares at September 30, 2018 and December 31, 2017; 1,969,797 shares issued and outstanding at September 30, 2018 and December 31, 2017                       | —                     | —                    |
| Common stock, par value \$0.0001 per share authorized: 200,000,000 at September 30, 2018 and December 31, 2017; 15,393,309 and 14,227,634 shares issued and outstanding at September 30, 2018 and December 31, 2017, respectively | 2                     | 1                    |
| Additional paid-in-capital  | 610,845               | 288,750              |
| Accumulated other comprehensive loss  | (143)                 | (31)                 |
| Accumulated deficit   | (127,797)             | (106,461)            |
| Total stockholders' equity  | 482,907               | 182,259              |
| Total liabilities and stockholders' equity  | \$ 489,549            | \$ 192,313           |

See accompanying notes to condensed consolidated financial statements.

**MADRIGAL PHARMACEUTICALS, INC.**  
**CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS**  
**(Unaudited; in thousands, except share and per share amounts)**

|   | <u>Three Months Ended September 30,</u> |                   | <u>Nine Months Ended September 30,</u> |                    |
|---|---|-------------------|--|--------------------|
|   | <u>2018</u>                             | <u>2017</u>       | <u>2018</u>                            | <u>2017</u>        |
| <b>Revenues:</b>  |   |                   |  |                    |
| Total revenues  | \$ —                                    | \$ —              | \$ —                                   | \$ —               |
| <b>Operating expenses:</b>  |   |                   |  |                    |
| Research and development  | 6,211                                   | 6,682             | 16,518                                 | 17,878             |
| General and administrative  | 5,122                                   | 1,955             | 9,710                                  | 5,273              |
| Total operating expenses  | 11,333                                  | 8,637             | 26,228                                 | 23,151             |
| Loss from operations  | (11,333)                                | (8,637)           | (26,228)                               | (23,151)           |
| Interest income   | 2,821                                   | 174               | 4,692                                  | 342                |
| Other income  | —                                       | 100               | 200                                    | 100                |
| Net loss  | <u>\$ (8,512)</u>                       | <u>\$ (8,363)</u> | <u>\$ (21,336)</u>                     | <u>\$ (22,709)</u> |
| <b>Net loss per common share:</b>                                 |   |                   |  |                    |
| Basic and diluted net loss per common share                       | \$ (0.56)                               | \$ (0.68)         | \$ (1.46)                              | \$ (1.87)          |
| <b>Basic and diluted weighted average number of common shares</b> |   |                   |  |                    |
| outstanding   | 15,307,872                              | 12,378,622        | 14,610,809                             | 12,126,004         |

See accompanying notes to condensed consolidated financial statements.

**MADRIGAL PHARMACEUTICALS, INC.**  
**CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS**  
**(Unaudited; in thousands)**

|   | <u>Three Months Ended September 30,</u> |                   | <u>Nine Months Ended September 30,</u> |                    |
|---|---|-------------------|--|--------------------|
|   | <u>2018</u>                             | <u>2017</u>       | <u>2018</u>                            | <u>2017</u>        |
| Net Loss  | \$ (8,512)                              | \$ (8,363)        | \$ (21,336)                            | \$ (22,709)        |
| Other comprehensive income (loss):                      |   |                   |  |                    |
| Unrealized gain (loss) on available-for-sale securities | (100)                                   | 11                | (112)                                  | 22                 |
| Comprehensive loss                                      | <u>\$ (8,612)</u>                       | <u>\$ (8,352)</u> | <u>\$ (21,448)</u>                     | <u>\$ (22,687)</u> |

See accompanying notes to condensed consolidated financial statements.

**MADRIGAL PHARMACEUTICALS, INC.**  
**CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS**  
(Unaudited; in thousands)

|  | <u>Nine Months Ended September 30,</u> |                  |
|--|--|------------------|
|  | <u>2018</u>                            | <u>2017</u>      |
| <b>Cash flows from operating activities:</b>                                       |  |                  |
| Net loss   | \$ (21,336)                            | \$ (22,709)      |
| <b>Adjustments to reconcile net loss to net cash used in operating activities:</b> |  |                  |
| Stock-based compensation expense   | 8,370                                  | 2,307            |
| Depreciation and amortization expense  | 71                                     | 17               |
| <b>Changes in operating assets and liabilities:</b>                                |  |                  |
| Prepaid expenses and other current assets  | (281)                                  | 290              |
| Accounts payable   | (898)                                  | 638              |
| Accrued expense  | (2,514)                                | 3,085            |
| Accrued interest, net of interest received on maturity of investments              | (2,654)                                | —                |
| Net cash used in operating activities  | <u>(19,242)</u>                        | <u>(16,372)</u>  |
| <b>Cash flows from investing activities:</b>                                       |  |                  |
| Purchases of marketable securities   | (524,935)                              | (34,910)         |
| Sales and maturities of marketable securities                                      | 119,885                                | 6,944            |
| Purchases of property and equipment, net of disposals                              | (14)                                   | (125)            |
| Net cash used in investing activities  | <u>(405,064)</u>                       | <u>(28,091)</u>  |
| <b>Cash flows from financing activities:</b>                                       |  |                  |
| Proceeds from issuance of stock, net of transaction costs                          | 311,825                                | 38,278           |
| Proceeds from exercise of common stock options                                     | 1,900                                  | —                |
| Net cash provided by financing activities  | <u>313,725</u>                         | <u>38,278</u>    |
| Net decrease in cash and cash equivalents  | <u>(110,581)</u>                       | <u>(6,185)</u>   |
| Cash and cash equivalents at beginning of period                                   | 148,627                                | 19,145           |
| Cash and cash equivalents at end of period   | <u>\$ 38,046</u>                       | <u>\$ 12,960</u> |

See accompanying notes to condensed consolidated financial statements.

**MADRIGAL PHARMACEUTICALS, INC.**  
**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**  
**(Unaudited)**

**1. Organization, Business, and Basis of Presentation**

**Organization and Business**

Madrigal Pharmaceuticals, Inc. (the “Company” or “Madrigal”) is a clinical-stage pharmaceutical company developing novel, high-quality, small-molecule drugs addressing major unmet needs in cardiovascular, metabolic, and liver diseases. The Company’s lead compound, MGL-3196, is being advanced for non-alcoholic steatohepatitis (“NASH”), a liver disease that commonly affects people with metabolic diseases such as obesity and diabetes, and indications in dyslipidemia, including genetic dyslipidemias such as familial hypercholesterolemia (“FH”). The Company initiated a Phase 2 study of MGL-3196 in NASH in October 2016. In February 2017, the Company initiated a Phase 2 study of MGL-3196 in patients with Heterozygous Familial Hypercholesterolemia (“HeFH”). Both Phase 2 studies were fully enrolled in 2017, the HeFH study was completed in February 2018, and the NASH study was completed in May 2018.

Madrigal was originally incorporated as a private company (“Private Madrigal”) on August 19, 2011 and commenced operations in September 2011. On July 22, 2016, Private Madrigal completed a reverse merger (the “Merger”) into Synta Pharmaceuticals Corp. (“Synta”). Upon the consummation of the Merger, the historical financial statements of Private Madrigal became the Company’s historical financial statements. The Company, or Madrigal, as used in the accompanying notes to the unaudited condensed consolidated financial statements, refers to Private Madrigal prior to the completion of the Merger and Public Madrigal subsequent to the completion of the Merger.

**Basis of Presentation**

Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) have been condensed or omitted. Accordingly, the unaudited condensed consolidated financial statements do not include all information and footnotes required by GAAP for complete annual financial statements. However, we believe that the disclosures included in these financial statements are adequate to make the information presented not misleading. The unaudited condensed financial statements, in the opinion of management, reflect all adjustments, which include normal recurring adjustments, necessary for a fair statement of such interim results. The interim results are not necessarily indicative of the results that we will have for the full year ended December 31, 2018 or any subsequent period. These unaudited condensed financial statements should be read in conjunction with the audited consolidated financial statements and the notes to those statements for the year ended December 31, 2017.

**2. Summary of Significant Accounting Policies**

**Principle of Consolidation**

The consolidated financial statements include the financial statements of the Company and its wholly owned subsidiaries. All significant intercompany balances have been eliminated in consolidation.

**Use of Estimates**

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect certain reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting periods. The Company bases its estimates on historical experience and various other assumptions that management believes to be reasonable under the circumstances. Changes in estimates are recorded in the period in which they become known. Actual results could differ from those estimates.

**Cash and Cash Equivalents**

The Company considers all highly liquid investments with original maturities of three months or less at the date of purchase to be cash equivalents. The Company maintains its cash in bank accounts, the balance of which, at times, exceeds Federal Deposit Insurance Corporation insured limits.

The primary objective of the Company’s investment activities is to preserve its capital for the purpose of funding operations and the Company does not enter into investments for trading or speculative purposes. The Company’s cash is deposited in highly rated financial institutions in the United States. The Company invests in money market funds and high-grade, short-term commercial paper and corporate bonds, which management believes are subject to minimal credit and market risk.

## Marketable Securities

Marketable securities consist of investments in high-grade corporate obligations and government and government agency obligations that are classified as available-for-sale. Since these securities are available to fund current operations, they are classified as current assets on the consolidated balance sheets.

The Company adjusts the cost of available-for-sale debt securities for amortization of premiums and accretion of discounts to maturity. The Company includes such amortization and accretion as a component of interest income, net. Realized gains and losses and declines in value, if any, that the Company judges to be other-than-temporary on available-for-sale securities are reported as a component of interest income, net. To determine whether an other-than-temporary impairment exists, the Company considers whether it intends to sell the debt security and, if the Company does not intend to sell the debt security, it considers available evidence to assess whether it is more likely than not that it will be required to sell the security before the recovery of its amortized cost basis. During the three and nine months ended September 30, 2018 and 2017, the Company determined it did not have any securities that were other-than-temporarily impaired.

Marketable securities are stated at fair value, including accrued interest, with their unrealized gains and losses included as a component of accumulated other comprehensive income or loss, which is a separate component of stockholders' equity. The fair value of these securities is based on quoted prices and observable inputs on a recurring basis. Realized gains and losses are determined on the specific identification method. During the three and nine months ended September 30, 2018 and 2017, the Company did not have any realized gains or losses on marketable securities.

## Fair Value of Financial Instruments

The carrying amounts of the Company's financial instruments, which include cash equivalents, and marketable securities, approximate their fair values. The fair value of the Company's financial instruments reflects the amounts that would be received upon sale of an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value hierarchy has the following three levels:

Level 1—quoted prices in active markets for identical assets and liabilities.

Level 2—observable inputs other than Level 1 inputs. Examples of Level 2 inputs include quoted prices in active markets for similar assets or liabilities and quoted prices for identical assets or liabilities in markets that are not active.

Level 3—unobservable inputs that reflect the Company's own assumptions about the assumptions market participants would use in pricing the asset or liability.

Financial assets and liabilities are classified in their entirety within the fair value hierarchy based on the lowest level of input that is significant to the fair value measurement. The Company measures the fair value of its marketable securities by taking into consideration valuations obtained from third-party pricing sources. The pricing services utilize industry standard valuation models, including both income and market based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate fair value. These inputs include reported trades of and broker-dealer quotes on the same or similar securities, issuer credit spreads, benchmark securities and other observable inputs. As of September 30, 2018, the Company's financial assets valued based on Level 1 inputs consisted of cash and cash equivalents in a money market fund and its financial assets valued based on Level 2 inputs consisted of high-grade corporate bonds and commercial paper. During the three and nine months ended September 30, 2018 and 2017, the Company did not have any transfers of financial assets between Levels 1 and 2. As of September 30, 2018 and December 31, 2017, the Company did not have any financial liabilities that were recorded at fair value on a recurring basis on the balance sheet.

## Research and Development Costs

Research and development costs are expensed as incurred. Research and development costs are comprised of costs incurred in performing research and development activities, including internal costs (including stock-based compensation), costs for consultants, and other costs associated with the Company's preclinical and clinical programs. In particular, Madrigal has conducted safety studies in animals, optimized and implemented the API manufacturing process, and conducted Phase 1 & 2 clinical trials, all of which are considered research and development expenditures.



## Patents

Costs to secure and defend patents are expensed as incurred and are classified as general and administrative expense in the Company's consolidated statements of operations.

## Stock-Based Compensation

The Company recognizes stock-based compensation expense based on the grant date fair value of stock options granted to employees, officers, and directors. The Company uses the Black-Scholes option pricing model to determine the grant date fair value as management believes it is the most appropriate valuation method for its option grants. The Black-Scholes model requires inputs for risk-free interest rate, dividend yield, volatility and expected lives of the options. The expected lives for options granted represent the period of time that options granted are expected to be outstanding. The Company uses the simplified method for determining the expected lives of options. Expected volatility is based upon an industry estimate or blended rate including the Company's historical trading activity. The risk-free rate for periods within the expected life of the option is based on the U.S. Treasury yield curve in effect at the time of the grant. The Company estimates the forfeiture rate based on historical data. This analysis is re-evaluated at least annually and the forfeiture rate is adjusted as necessary.

Certain of the employee stock options granted by the Company are structured to qualify as incentive stock options ("ISOs"). Under current tax regulations, the Company does not receive a tax deduction for the issuance, exercise or disposition of ISOs if the employee meets certain holding requirements. If the employee does not meet the holding requirements, a disqualifying disposition occurs, at which time the Company may receive a tax deduction. The Company does not record tax benefits related to ISOs unless and until a disqualifying disposition is reported. In the event of a disqualifying disposition, the entire tax benefit is recorded as a reduction of income tax expense. The Company has not recognized any income tax benefit for its share-based compensation arrangements due to the fact that the Company does not believe it is more likely than not it will realize the related deferred tax assets.

## Income Taxes

The Company uses the asset and liability method to account for income taxes. Deferred tax assets and liabilities are determined based on the expected future tax consequences of temporary differences between the Company's financial statement carrying amounts and the tax basis of assets and liabilities using enacted tax rates expected to be in effect in the years in which the differences are expected to reverse. The Company currently maintains a 100% valuation allowance on its deferred tax assets.

## Comprehensive Loss

Comprehensive loss is defined as the change in equity of a business enterprise during a period from transactions and other events and circumstances from non-owner sources. Changes in unrealized gains and losses on marketable securities represent the only difference between the Company's net loss and comprehensive loss.

## Basic and Diluted Loss Per Common Share

Basic net loss per share is computed using the weighted average number of common shares outstanding during the period, excluding restricted stock that has been issued but is not yet vested. Diluted net loss per common share is computed using the weighted average number of common shares outstanding and the weighted average dilutive potential common shares outstanding using the treasury stock method. However, for the three and nine months ended September 30, 2018 and 2017, diluted net loss per share is the same as basic net loss per share because the inclusion of weighted average shares of unvested restricted common stock, common stock issuable upon the exercise of stock options, and common stock issuable upon the conversion of preferred stock would be anti-dilutive.

The following table summarizes outstanding securities not included in the computation of diluted net loss per common share, as their inclusion would be anti-dilutive:

|                                  | <b>Nine Months Ended September 30,</b> |             |
|----------------------------------|--|-------------|
|                                  | <b>2018</b>                            | <b>2017</b> |
| Common Stock Options             | 1,123,582                              | 991,711     |
| Unvested Restricted Common Stock | 52,063                                 | 105,199     |
| Preferred Stock                  | 1,969,797                              | 1,969,797   |

## Recent Accounting Pronouncements

In June 2018, The Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") No. 2018-07, "Improvements to Nonemployee Share-Based Payment Accounting" to simplify the accounting for share-based payment transactions with non-employees of the Company. The guidance within this accounting standard update generally requires that share-based payment transactions for acquiring goods or services from non-employees of the Company be accounted for under the same

guidance and model as all other share-based payment transactions, including employees of the Company. For public business entities, ASU 2018-07 is effective for annual and interim reporting periods beginning after December 15, 2018, with early adoption permitted. The Company elected to early adopt the guidance within this accounting standard update in the second quarter of 2018. There was no significant impact from the adoption.

In May 2017, the FASB issued ASU No. 2017-09, “Compensation—Stock Compensation (Topic 718): Scope of Modification Accounting,” to provide clarity and reduce both diversity in practice, and cost and complexity when a change is made to the terms or conditions of a share-based payment award. For public business entities, ASU 2017-09 is effective for annual and interim reporting periods beginning after December 15, 2017, with early adoption permitted. The update should be applied prospectively to an award modified on or after the adoption date. The Company adopted ASU No. 2017-09 effective January 1, 2018. There was no significant impact from the adoption.

In August 2016, the FASB issued ASU No. 2016-15, “Statement of Cash Flows (Topic 230): Clarification of Certain Cash Receipts and Cash Payments.” The objective of ASU No. 2016-15 is to eliminate the diversity in practice related to the classification of certain cash receipts and payments in the statement of cash flows, by adding or clarifying guidance on eight specific cash flow issues. For public business entities, ASU 2016-15 is effective for annual and interim reporting periods beginning after December 15, 2017, with early adoption permitted. ASU 2016-15 provides that the amendments in the update should be applied retrospectively to all periods presented, unless deemed impracticable, in which case, prospective application is permitted. The Company adopted ASU No. 2016-15 effective January 1, 2018. There was no significant impact from the adoption.

In January 2016, the FASB issued ASU No. 2016-01, “Financial Instruments—Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities,” which amends the guidance in U.S. generally accepted accounting principles on the classification and measurement of financial instruments. Changes to the prior guidance primarily affect the accounting for equity investments, financial liabilities under the fair value option, and the presentation and disclosure requirements for financial instruments. In addition, the ASU clarifies guidance related to the valuation allowance assessment when recognizing deferred tax assets resulting from unrealized losses on available-for-sale debt securities. The amendments in this ASU are effective for fiscal years and interim periods beginning after December 15, 2017, and are to be adopted by means of a cumulative-effect adjustment to the balance sheet at the beginning of the first reporting period in which the guidance is effective. Early adoption is not permitted except for the provision to record fair value changes for financial liabilities under the fair value option resulting from instrument-specific credit risk in other comprehensive income. The Company adopted ASU No. 2016-01 effective January 1, 2018. There was no significant impact from the adoption.

### **3. Liquidity and Uncertainties**

The Company is subject to risks common to development stage companies in the biopharmaceutical industry including, but not limited to, uncertainty of product development and commercialization, dependence on key personnel, uncertainty of market acceptance of products and product reimbursement, product liability, uncertain protection of proprietary technology, potential inability to raise additional financing necessary for development and commercialization, and compliance with the U.S. Food and Drug Administration and other government regulations.

The Company has incurred losses since inception, including approximately \$21.3 million for the nine months ended September 30, 2018, resulting in an accumulated deficit of approximately \$127.8 million as of September 30, 2018. Management expects to incur losses for the foreseeable future. To date, the Company has funded its operations primarily through the issuance of convertible debt, the proceeds from the Merger on July 22, 2016, and proceeds from sales of the Company’s equity securities (see Note 5).

The Company believes that its cash, cash equivalents and marketable securities at September 30, 2018 will be sufficient to fund operations past one year from the issuance of these financial statements. To meet its future capital needs, the Company intends to raise additional capital through debt or equity financings, collaborations, partnerships or other strategic transactions. However, there can be no assurance that the Company will be able to complete any such transactions on acceptable terms or otherwise. The inability of the Company to obtain sufficient funds on acceptable terms when needed could have a material adverse effect on the Company’s business, results of operations and financial condition. The Company has the ability to delay certain research activities and related clinical expenses if necessary due to liquidity concerns until a date when those concerns are relieved.

**4. Cash, Cash Equivalents and Marketable Securities**

A summary of cash, cash equivalents and available-for-sale marketable securities held by the Company as of September 30, 2018 and December 31, 2017 is as follows (in thousands):

|   | September 30, 2018       |                         |                          |                   |
|---|--------------------------|-------------------------|--------------------------|-------------------|
|   | Cost                     | Unrealized gains        | Unrealized losses        | Fair value        |
| <b>Cash and cash equivalents:</b>   |                          |                         |                          |                   |
| Cash (Level 1)  | \$ 2,127                 | \$ —                    | \$ —                     | \$ 2,127          |
| Money market funds (Level 1)  | 35,919                   | —                       | —                        | 35,919            |
| Corporate debt securities due within 3 months of date of purchase (Level 2)           | —                        | —                       | —                        | —                 |
| <b>Total cash and cash equivalents</b>  | <b>38,046</b>            | <b>—</b>                | <b>—</b>                 | <b>38,046</b>     |
| <b>Marketable securities:</b>   |                          |                         |                          |                   |
| Corporate debt securities due within 1 year of date of purchase (Level 2)             | 437,106                  | 13                      | (144)                    | 436,975           |
| Corporate debt securities due between 1 and 2 years of the date of purchase (Level 2) | 13,529                   | —                       | (12)                     | 13,517            |
| <b>Total cash, cash equivalents and marketable securities</b>                         | <b>\$ 488,681</b>        | <b>\$ 13</b>            | <b>\$ (156)</b>          | <b>\$ 488,538</b> |
|   | <b>December 31, 2017</b> |                         |                          |                   |
|   | <b>Cost</b>              | <b>Unrealized Gains</b> | <b>Unrealized losses</b> | <b>Fair value</b> |
| <b>Cash and cash equivalents:</b>   |                          |                         |                          |                   |
| Cash (Level 1)  | \$ 2,725                 | \$ —                    | \$ —                     | \$ 2,725          |
| Money market funds (Level 1)  | 145,902                  | —                       | —                        | 145,902           |
| Corporate debt securities due within 3 months of date of purchase (Level 2)           | —                        | —                       | —                        | —                 |
| <b>Total cash and cash equivalents</b>  | <b>148,627</b>           | <b>—</b>                | <b>—</b>                 | <b>148,627</b>    |
| <b>Marketable securities:</b>   |                          |                         |                          |                   |
| Corporate debt securities due within 1 year of date of purchase (Level 2)             | 42,931                   | —                       | (31)                     | 42,900            |
| <b>Total cash, cash equivalents and marketable securities</b>                         | <b>\$ 191,558</b>        | <b>\$ —</b>             | <b>\$ (31)</b>           | <b>\$ 191,527</b> |

**5. Stockholders' Equity****Common Stock**

Each common stockholder is entitled to one vote for each share of common stock held. The common stock will vote together with all other classes and series of stock of the Company as a single class on all actions to be taken by the Company's stockholders. Each share of common stock is entitled to receive dividends, as and when declared by the Company's board of directors.

The Company has never declared cash dividends on its common stock and does not expect to do so in the foreseeable future.

**June 2018 Registered Offering of Common Stock**

In June 2018, the Company entered into an underwriting agreement with Goldman Sachs & Co. LLC, as representative of the several underwriters named therein (the "June 2018 Underwriters"), relating to an underwritten public offering (the "June 2018 Offering") of 1,079,580 shares of the Company's common stock, including 95,973 shares of the Company's common stock purchased by the June 2018 Underwriters pursuant to a 30-day option to purchase such additional shares granted therein, at a public offering price of \$305.00 per share. The June 2018 Offering resulted in net proceeds to the Company of approximately \$311.8 million, after deducting the June 2018 Underwriters' discount and other offering costs. The June 2018 Offering closed on June 11, 2018.

**December 2017 Registered Offering of Common Stock**

In December 2017, the Company entered into an underwriting agreement with Goldman Sachs & Co. LLC, as representative of the several underwriters named therein (the "December 2017 Underwriters"), relating to an underwritten public offering (the

“December 2017 Offering”) of 1,731,929 shares of the Company’s common stock, including 225,904 shares of the Company’s common stock purchased by the December 2017 Underwriters pursuant to a 30-day option to purchase such additional shares granted therein, at a public offering price of \$83.00 per share. The December 2017 Offering resulted in net proceeds to the Company of approximately \$135.5 million, after deducting the December 2017 Underwriters’ discount and other offering costs. The December 2017 Offering closed on December 21, 2017.

#### ***June 2017 Private Placement Offering of Common Stock and Series A Convertible Preferred Stock***

In June 2017, the Company entered into a Securities Purchase Agreement (the “Purchase Agreement”) with a group of institutional accredited investors, who were existing, non-controlling stockholders of the Company, pursuant to which the Company sold securities to the Investors in a private placement transaction (the “June 2017 Offering”). Under the terms of the Purchase Agreement, the Company sold 328,300 shares of its common stock at a price of \$15.23 per share, and 1,969,797 shares of its Series A Convertible Preferred Stock (the “Series A Preferred Stock”) at a price of \$15.23 per share. The June 2017 Offering resulted in gross proceeds to the Company of approximately \$35.0 million, and net proceeds to the Company of approximately \$34.9 million. The June 2017 Offering closed on June 23, 2017.

The Series A Preferred Stock has a par value of \$0.0001 per share and is convertible into shares of the common stock at a one-to-one ratio, subject to adjustment as provided in the Purchase Agreement. The terms of the Series A Preferred Stock are set forth in the Certificate of Designation of Preferences, Rights and Limitations of Series A Convertible Preferred Stock, that the Company filed with the Secretary of State of the State of Delaware on June 21, 2017. Each share of the Series A Preferred Stock is convertible into shares of Common Stock at any time at the holder’s option. Upon any liquidation, dissolution or winding-up of the Company, whether voluntary or involuntary, after the satisfaction in full of the debts of the Company and the payment of any liquidation preference owed to the holders of shares of capital stock of the Company ranking prior to the Series A Preferred Stock upon liquidation, the holders of the Series A Preferred Stock shall participate pari passu with the holders of the Common Stock (on an as-if-converted-to-Common-Stock basis) in the net assets of the Company. Shares of the Series A Preferred Stock will generally have no voting rights, except as required by law. Shares of the Series A Preferred Stock will be entitled to receive dividends before shares of any other class or series of capital stock of the Company (other than dividends in the form of the Common Stock) equal to the dividend payable on each share of the Common Stock, on an as-converted basis.

#### ***At-The-Market Issuance Sales Agreement***

In October 2015, the Company entered into an at-the-market issuance sales agreement (the “October 2015 Sales Agreement”), with Cowen and Company, LLC (“Cowen”), pursuant to which the Company may issue and sell shares of its common stock, having an aggregate offering price of up to \$100 million, from time to time, at the Company’s option, through Cowen as its sales agent. Sales of common stock through Cowen may be made by any method that is deemed an “at-the-market” offering as defined in Rule 415 promulgated under the Securities Act of 1933, as amended, including by means of ordinary brokers’ transactions at market prices, in block transactions or as otherwise agreed by the Company and Cowen. Subject to the terms and conditions of the October 2015 Sales Agreement, Cowen will use commercially reasonable efforts consistent with its normal trading and sales practices to sell the common stock based upon the Company’s instructions (including any price, time or size limits or other customary parameters or conditions the Company may impose). The Company is not obligated to make any sales of its common stock under the October 2015 Sales Agreement. Any shares sold will be sold pursuant to an effective shelf registration statement on Form S-3 (file no. 333-206135). The Company will pay Cowen a commission of up to 3% of the gross proceeds. The October 2015 Sales Agreement may be terminated by the Company at any time upon 10 days’ notice.

As of September 30, 2018, 597,256 shares have been sold under the October 2015 Sales Agreement for an aggregate of approximately \$9.6 million in gross proceeds. Net proceeds to the Company were approximately \$9.4 million after deducting commissions and other transactions costs. Of those shares sold, none were sold in 2018, and 215,539 were sold in 2017. Approximately \$90.4 million remained reserved under the Company’s shelf registration statement and the applicable prospectus supplement for possible future issuance under the October 2015 Sales Agreement.

## **6. Stock-based Compensation**

In June 2015, upon obtaining stockholder approval at its annual shareholder meeting, the Company implemented its new 2015 Stock Plan. The 2015 Stock Plan replaced the 2006 Stock Plan, which was terminated upon adoption of the 2015 Stock Plan. Shares of common stock reserved for outstanding awards under the 2006 Stock Plan that lapse or are canceled will be added back to the share reserve available for future awards under the 2015 Stock Plan. The 2015 Stock Plan provides for the grant of incentive stock options, non-statutory stock options, restricted stock and other stock-based compensation awards to employees, officers, directors, and consultants of the Company. The administration of the 2015 Stock Plan is under the general supervision of the compensation committee of the board of directors. The exercise price of the stock options is determined by the compensation committee of the board of directors, provided that incentive stock options are granted with an exercise price not less than fair market value of the common

stock on the date of grant and expire no later than ten years from the date the option is granted. As of September 30, 2018, the Company had options outstanding to purchase 1,123,582 shares of its common stock, which includes options outstanding under its 2006 Stock Plan that was terminated in June 2015. As of September 30, 2018, 1,225,595 shares were available for future issuance.

The following table summarizes stock option activity during the nine months ended September 30, 2018:

|                                   | Shares           | Weighted<br>average<br>exercise<br>price |
|-----------------------------------|------------------|--|
| Outstanding at January 1, 2018    | 976,777          | \$ 11.97                                 |
| Options granted                   | 241,650          | 173.23                                   |
| Options exercised                 | (86,095)         | 22.06                                    |
| Options canceled                  | (8,750)          | 113.81                                   |
| Outstanding at September 30, 2018 | <u>1,123,582</u> | <u>\$ 45.09</u>                          |
| Exercisable at September 30, 2018 | <u>621,000</u>   | <u>\$ 10.75</u>                          |

The total cash received by the Company as a result of stock option exercises was \$1.9 million and \$0, respectively, for the nine months ended September 30, 2018 and 2017. The weighted-average grant date fair values, based on the Black-Scholes option model, of options granted during the nine months ended September 30, 2018 and 2017 were \$136.43 and \$13.30, respectively.

### Restricted Common Stock

The Company's share-based compensation plan provides for awards of restricted shares of common stock to employees, officers, directors and consultants to the Company. Restricted stock awards are subject to forfeiture if employment or service terminates during the prescribed retention period. Restricted shares vest over the service period.

The following table summarizes unvested restricted share activity during the nine months ended September 30, 2018:

|                                   | Shares        | Weighted<br>average<br>exercise<br>price |
|-----------------------------------|---------------|--|
| Outstanding at January 1, 2018    | 104,127       | \$ 9.45                                  |
| Granted                           | —             | —  |
| Vested                            | (52,064)      | 9.45                                     |
| Forfeited                         | —             | —  |
| Outstanding at September 30, 2018 | <u>52,063</u> | <u>\$ 9.45</u>                           |

### Stock-Based Compensation Expense

Stock-based compensation expense during the three and nine months ended September 2018 and 2017 was as follows (in thousands):

|   | Three Months Ended September 30, |                 | Nine Months Ended September 30, |                 |
|---|----------------------------------|-----------------|---------------------------------|-----------------|
|   | 2018                             | 2017            | 2018                            | 2017            |
| Stock-based compensation expense by type of award:          |                                  |                 |                                 |                 |
| Stock options   | \$ 4,852                         | \$ 878          | \$ 8,002                        | \$ 1,859        |
| Restricted stock  | 124                              | 151             | 368                             | 448             |
| Total stock-based compensation expense                      | <u>\$ 4,976</u>                  | <u>\$ 1,029</u> | <u>\$ 8,370</u>                 | <u>\$ 2,307</u> |
| Effect of stock-based compensation expense by line item:    |                                  |                 |                                 |                 |
| Research and development                                    | \$ 1,179                         | \$ 272          | \$ 2,287                        | \$ 577          |
| General and administrative                                  | 3,797                            | 757             | 6,083                           | 1,730           |
| Total stock-based compensation expense included in net loss | <u>\$ 4,976</u>                  | <u>\$ 1,029</u> | <u>\$ 8,370</u>                 | <u>\$ 2,307</u> |

Unrecognized stock-based compensation expense as of September 30, 2018 was as follows (in thousands):

|                  | Unrecognized<br>stock<br>compensation<br>expense | Weighted<br>average<br>remaining<br>period<br>(in years) |
|------------------|--|--|
| Stock options    | \$ 25,250  | 2.23   |
| Restricted stock | 396  | 0.80   |
| Total            | <u>\$ 25,646</u>                                 | <u>2.21</u>  |

## 7. Commitments and Contingencies

The Company has a Research, Development and Commercialization Agreement with Hoffmann-La Roche (“Roche”) which grants the Company a sole and exclusive license to develop, use, sell, offer for sale and import any Licensed Product as defined by the agreement.

The agreement requires future milestone payments to Roche, the remainder of which total \$10 million and are earned by the commencement of Phase 3 clinical trials as well as future regulatory approval in the United States and Europe of a product developed from MGL-3916. A single-digit royalty payment range is based on net sales of products developed from MGL-3196, subject to certain reductions. In October 2016, the Company commenced a Phase 2 study in Non-Alcoholic Steatohepatitis (NASH), which triggered a milestone payment under the agreement. Except as described above, the Company has not achieved any additional product development or regulatory milestones to date and has no Licensed Product sales for the nine months ended September 30, 2018 and 2017.

The Company has entered into customary contractual arrangements and letters of intent in preparation for and in support of the Phase 2 and 3 clinical trials.

## SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS

This Quarterly Report on Form 10-Q contains forward-looking statements that are based on our beliefs and assumptions and on information currently available to us. Forward-looking statements include information with respect to our clinical trials, research and development activities, the timing and success of future development of MGL-3196, our possible or assumed future results of operations and expenses, business strategies and plans, capital needs and financing plans, trends, market sizing, competitive position, industry environment and potential growth opportunities, among other things. Forward-looking statements include all statements that are not historical facts and, in some cases, can be identified by terms such as “anticipates,” “believes,” “could,” “estimates,” “expects,” “intends,” “may,” “plans,” “potential,” “predicts,” “projects,” “seeks,” “should,” “will,” “would” or similar expressions and the negatives of those terms.

Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements, including those described in “Risk Factors” and elsewhere in this report. Given these uncertainties, you should not place undue reliance on these forward-looking statements.

Any forward-looking statement made by us in this report speaks only as of the date on which it is made. Except as required by law, we disclaim any obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.

### **Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.**

*The consolidated financial statements, included elsewhere in this Quarterly Report on Form 10-Q, and this Management’s Discussion and Analysis of Financial Condition and Results of Operations should be read together with our audited financial statements and accompanying notes for year ended December 31, 2017 and the related Management’s Discussion and Analysis of Financial Condition and Results of Operations, both of which are included in our Annual Report on Form 10-K. In addition to historical information, this discussion and analysis contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act, that involve risks and uncertainties, such as statements of our plans, objectives, expectations and intentions. Our actual results could differ materially from those discussed in these forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those discussed in the sections entitled “Risk Factors” included elsewhere in this report. Our operating results are not necessarily indicative of results that may occur for the full fiscal year or any other future period.*

### **About Madrigal Pharmaceuticals, Inc.**

We are a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Our lead product candidate, MGL-3196, is a proprietary, liver-directed, selective thyroid hormone receptor- $\beta$ , or THR- $\beta$ , agonist being developed as a once-daily oral pill that can potentially be used to treat a number of disease states with high unmet medical need, including non-alcoholic steatohepatitis, or NASH. For NASH, we enrolled 125 patients in a Phase 2 clinical trial. We achieved the 12-week primary endpoint for this Phase 2 clinical trial and reported the results in December 2017, and we reported positive topline 36-week results at the conclusion of the Phase 2 clinical trial in May 2018. We have an ongoing 36-week, open-label extension study in 31 participating NASH patients from the Phase 2 clinical trial, which includes 14 patients who received placebo in the main study. We are also developing MGL-3196 for dyslipidemia, including genetic dyslipidemias such as heterozygous familial hypercholesterolemia, or HeFH. We enrolled 116 patients and completed a Phase 2 clinical trial in HeFH patients, and we reported the results in February 2018. In addition to the NASH and HeFH Phase 2 clinical trials, MGL-3196 has also been studied in six completed Phase 1 trials in a total of 183 subjects. MGL-3196 appeared to be safe and was well-tolerated in these trials, which included a single ascending dose trial, a multiple ascending dose trial, two drug interaction trials with statins, a multiple dose mass balance study, and a single dose relative bioavailability study of tablet formulations versus capsule formulation.

## **Basis of Presentation**

### ***Research and Development Expenses***

Research and development expenses primarily consist of costs associated with our research activities, including the preclinical and clinical development of our product candidates. We expense our research and development expenses as incurred. We contract with clinical research organizations to manage our clinical trials under agreed upon budgets for each study, with oversight by our clinical program managers. We account for nonrefundable advance payments for goods and services that will be used in future research and development activities as expenses when the service has been performed or when the goods have been received. Manufacturing expense includes costs associated with drug formulation development and drug production. We do not track employee and facility related research and development costs by project, as we typically use our employee and infrastructure resources across multiple research and development programs. We believe that the allocation of such costs would be arbitrary and not be meaningful.

Our research and development expenses consist primarily of:

- external expenses paid to clinical trial sites, contract research organizations, laboratories, database software providers and consultants that conduct clinical trials;
- expenses related to development and production of nonclinical and clinical trial supplies, including fees paid to contract manufacturers;
- expenses related to preclinical studies;
- expenses related to compliance with drug development regulatory requirements; and
- other allocated expenses, which include direct and allocated expenses for depreciation of equipment and other supplies.

We expect to continue to incur substantial expenses related to our development activities for the foreseeable future as we initiate our Phase 3 clinical program and continue to conduct our Phase 2 clinical program and manufacturing and toxicology studies. Product candidates in later stages of clinical development generally have higher development costs than those in earlier stages of clinical development, due primarily to the increased size and duration of later-stage clinical trials, additional drug manufacturing requirements, and later stage toxicology studies such as carcinogenicity studies. Our research and development expenses increased between 2017 and 2018, and we expect that our research and development expenses will increase substantially in the future. The process of conducting preclinical studies and clinical trials necessary to obtain regulatory approval is costly and time consuming. The probability of success for each product candidate is affected by numerous factors, including preclinical data, clinical data, competition, manufacturing capability and commercial viability. Accordingly, we may never succeed in achieving marketing approval for any of our product candidates.

Completion dates and costs for our clinical development programs as well as our research program can vary significantly for each current and future product candidate and are difficult to predict. As a result, we cannot estimate with any degree of certainty the costs we will incur in connection with the development of our product candidates at this point in time. We expect that we will make determinations as to which programs and product candidates to pursue and how much funding to direct to each program and product candidate on an ongoing basis in response to the scientific success of early research programs, results of ongoing and future clinical trials, our ability to enter into collaborative agreements with respect to programs or potential product candidates, as well as ongoing assessments as to each current or future product candidate's commercial potential.

### ***General and Administrative Expenses***

General and administrative expenses consist primarily of management costs, costs associated with obtaining and maintaining our patent portfolio, professional fees for accounting, auditing, consulting and legal services, and allocated overhead expenses.

We expect that our general and administrative expenses may increase in the future as we expand our operating activities, maintain and expand our patent portfolio and incur additional costs associated with being a public company and maintaining compliance with exchange listing and U.S. Securities and Exchange Commission, or SEC, requirements. We expect these potential increases will likely include management costs, legal fees, accounting fees, directors' and officers' liability insurance premiums and expenses associated with investor relations.

### **Critical Accounting Policies and Estimates**

Our management's discussion and analysis of our financial condition and results of operations are based on our financial statements, which have been prepared in accordance with generally accepted accounting principles in the United States. The preparation of these financial statements requires us to make estimates and judgments that affect the reported amount of assets, liabilities, and expenses



and the disclosure of contingent assets and liabilities as of the date of the financial statements. On an ongoing basis, we evaluate our estimates and judgments, including those related to accrued research and development expenses and stock-based compensation expense. We base our estimates on historical experience, known trends and events, and various other factors that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ materially from these estimates under different assumptions or conditions. There have been no material changes in our critical accounting policies and significant judgments and estimates during the nine months ended September 30, 2018, as compared to those disclosed in our Annual Report on Form 10-K for the fiscal year ended December 31, 2017 filed with the SEC on March 13, 2018.

## Results of Operations

### Three Months Ended September 30, 2018 and 2017

The following table provides comparative unaudited results of operations for the three months ended September 30, 2018 and 2017 (in thousands):

|                                     | Three Months Ended<br>September 30, |          | Increase / (Decrease) |        |
|-------------------------------------|-------------------------------------|----------|-----------------------|--------|
|                                     | 2018                                | 2017     | \$                    | %      |
| Research and Development Expenses   | \$ 6,211                            | \$ 6,682 | (471)                 | (7)%   |
| General and Administrative Expenses | 5,122                               | 1,955    | 3,167                 | 162%   |
| Interest Income                     | (2,821)                             | (174)    | 2,647                 | 1521%  |
| Other Income                        | —                                   | (100)    | (100)                 | (100)% |
|                                     | \$ 8,512                            | \$ 8,363 |                       |        |

#### Revenue

We had no revenue for the three months ended September 30, 2018 and 2017.

#### Research and Development Expenses

Our research and development expenses were \$6.2 million for the three months ended September 30, 2018, compared to \$6.7 million in the corresponding period in 2017. Research and development expenses decreased by \$0.5 million in the 2018 period due primarily to the completion of treatment in our Phase 2 clinical trials in 2018. We expect our research and development expenses to increase over time as we advance our clinical and preclinical development programs for MGL-3196.

#### General and Administrative Expenses

Our general and administrative expenses were \$5.1 million for the three months ended September 30, 2018, compared to \$2.0 million in the corresponding period in 2017. General and administrative expenses increased by \$3.1 million in the 2018 period due primarily to an increase in non-cash stock compensation from stock option awards. We believe our general and administrative expenses may increase over time as we advance our clinical and preclinical development programs for MGL-3196, which will likely result in an increase in our headcount, consulting services, and related overhead needed to support those efforts.

#### Interest Income

Our net interest income was \$2.8 million for the three months ended September 30, 2018, compared to \$0.2 million for the three months ended September 30, 2017. The increase in interest income was due primarily to a higher average principal balance in our investment account in 2018, and increased interest rates.

**Nine Months Ended September 30, 2018 and 2017**

The following table provides comparative unaudited results of operations for the nine months ended September 30, 2018 and 2017 (in thousands):

|                                     | Nine Months Ended September<br>30, |                  | Increase / (Decrease) |       |
|-------------------------------------|------------------------------------|------------------|-----------------------|-------|
|                                     | 2018                               | 2017             | \$                    | %     |
| Research and Development Expenses   | \$ 16,518                          | \$ 17,878        | (1,360)               | (8)%  |
| General and Administrative Expenses | 9,710                              | 5,273            | 4,437                 | 84%   |
| Interest Income                     | (4,692)                            | (342)            | 4,350                 | 1272% |
| Other Income                        | (200)                              | (100)            | 100                   | 100%  |
|                                     | <u>\$ 21,336</u>                   | <u>\$ 22,709</u> |                       |       |

**Revenue**

We had no revenue for the nine months ended September 30, 2018 and 2017.

**Research and Development Expenses**

Our research and development expenses were \$16.5 million for the nine months ended September 30, 2018, compared to \$17.9 million in the corresponding period in 2017. Research and development expenses decreased by \$1.4 million in the 2018 period due primarily to the completion of treatment in our Phase 2 clinical trials in 2018. We expect our research and development expenses to increase over time as we advance our clinical and preclinical development programs for MGL-3196.

**General and Administrative Expenses**

Our general and administrative expenses were \$9.7 million for the nine months ended September 30, 2018, compared to \$5.3 million in the corresponding period in 2017. General and administrative expenses increased by \$4.4 million in the 2018 period due primarily to an increase in non-cash stock compensation from stock option awards. We believe our general and administrative expenses may increase over time as we advance our clinical and preclinical development programs for MGL-3196, which will likely result in an increase in our headcount, consulting services, and related overhead needed to support those efforts.

**Interest Income**

Our net interest income was \$4.7 million for the nine months ended September 30, 2018, compared to \$0.3 million for the nine months ended September 30, 2017. The increase in interest income was due primarily to a higher average principal balance in our investment account in 2018, and increased interest rates.

**Liquidity and Capital Resources**

As of September 30, 2018, we had cash, cash equivalents and marketable securities totaling \$488.5 million compared to \$191.5 million as of December 31, 2017, with the increase primarily attributable to the proceeds from the June 2018 Offering, partially offset by our cash used in operating activities. To date, we have funded our operations primarily through the issuance of convertible debt, the issuance of shares of common stock and preferred stock, and the proceeds from the merger with Synta.

Our most significant use of capital pertains to salaries and benefits for our employees, including clinical, scientific, operational, financial and management personnel, and external research and development expenses, such as clinical trials and preclinical activity related to our product candidates. Our cash and investment balances are held in a variety of interest bearing instruments, including obligations of U.S. government agencies, U.S. Treasury debt securities, corporate debt securities and money market funds. Cash in excess of immediate requirements is invested in accordance with our investment policy with a view toward capital preservation and liquidity.

We anticipate continuing to incur operating losses for the foreseeable future. While our rate of cash usage may increase in the future, in particular to support our product development and clinical trial efforts, we believe our available cash resources as of September 30,

2018 will be sufficient to fund our operations past one year from the issuance of the financial statements contained herein. Future capital requirements will be substantial and will depend on many factors. To meet future capital requirements, we will need to raise additional capital to fund our operations through equity or debt financing. We regularly consider fundraising opportunities and may decide, from time to time, to raise capital based on various factors, including market conditions and our plans of operation. Additional capital may not be available on terms acceptable to us, or at all. If adequate funds are not available, or if the terms of potential funding sources are unfavorable, our business and our ability to develop our product candidates would be harmed. Furthermore, any sales of additional equity securities may result in dilution to our stockholders, and any debt financing may include covenants that restrict our business.

### **Cash Flows**

The following table provides a summary of our net cash flow activity (in thousands):

|   | <b>Nine Months Ended September 30,</b> |             |
|---|--|-------------|
|   | <b>2018</b>                            | <b>2017</b> |
| Net cash used in operating activities     | \$ (19,242)                            | \$ (16,372) |
| Net cash used by investing activities     | (405,064)                              | (28,091)    |
| Net cash provided by financing activities | 313,725                                | 38,278      |
| Net decrease in cash and cash equivalents | \$ (110,581)                           | \$ (6,185)  |

Net cash used in operating activities was \$19.2 million for the nine months ended September 30, 2018, compared to \$16.4 million for the nine months ended September 30, 2017. The use of cash in these periods resulted primarily from our losses from operations, as adjusted for non-cash charges for stock-based compensation, and changes in our working capital accounts.

Net cash used in investing activities was \$405.1 million for the nine months ended September 30, 2018, compared to \$28.1 million used in investing activities for the nine months ended September 30, 2017. Net cash used by investing activities for the nine months ended September 30, 2018 consisted of \$524.9 million of purchases of marketable securities for our investment portfolio, partially offset by \$119.9 million from sales and maturities of marketable securities. Net cash used by investing activities for the nine months ended September 30, 2017 consisted of \$34.9 million of purchases of marketable securities for our investment portfolio, partially offset by \$6.9 million from sales and maturities of marketable securities.

Net cash provided by financing activities was \$313.7 million for the nine months ended September 30, 2018, compared to \$38.3 million for the nine months ended September 30, 2017. Net cash provided by financing activities for the nine months ended September 30, 2018 consisted of net proceeds from the issuance of common stock pursuant to the June 2018 Offering and the exercise of stock options. Net cash provided by financing activities for the nine months ended September 30, 2017 consisted of net proceeds from the sale of common stock under the October 2015 Sales Agreement and net proceeds from the sale of preferred stock and common stock in the June 2017 Offering.

### **Contractual Obligations and Commitments**

No significant changes to contractual obligations and commitments occurred during the nine months ended September 30, 2018, as compared to those disclosed in our Annual Report on Form 10-K for the fiscal year ended December 31, 2017, filed with the SEC on March 13, 2018.

### **Off-Balance Sheet Arrangements**

We do not have any off-balance sheet arrangements as defined in the rules and regulations of the SEC.

### **Item 3. Quantitative and Qualitative Disclosures About Market Risk.**

#### **Interest Rate Risk**

Our cash, cash equivalents and marketable securities as of September 30, 2018 consisted of readily available checking account balances, money market funds, and high-grade corporate and government obligations that are classified as available-for-sale. Our primary exposure to market risk is interest income sensitivity, which is affected by changes in the general level of U.S. interest rates. However, because of the short-term nature of the instruments in our portfolio, a sudden change in market interest rates would not be expected to have a material impact on our financial condition and/or results of operations. We do not believe that our cash, cash

equivalents and marketable securities have a significant risk of default or illiquidity. While we believe our cash, cash equivalents and marketable securities do not contain excessive risk, we cannot provide absolute assurance that in the future our investments will not be subject to adverse changes in market value. In addition, we maintain significant amounts of cash and cash equivalents at one or more financial institutions that are in excess of federally insured limits.

### ***Effects of Inflation***

Inflation generally affects us with increased cost of labor and clinical trial costs. We do not believe that inflation and changing prices had a significant impact on our results of operations for any periods presented herein.

## **Item 4. Controls and Procedures.**

### ***Definition and Limitations of Disclosure Controls***

Our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) are designed to provide reasonable assurance that information required to be disclosed by us in the reports that we file under the Exchange Act, such as this Quarterly Report, is recorded, processed, summarized and reported within the time periods specified in the SEC's rules and forms and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. Our management evaluates these controls and procedures on an ongoing basis.

We carried out an evaluation, under the supervision of and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures as of the end of the period covered by this Quarterly Report. Based on the foregoing, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective at the reasonable assurance level.

### ***Limitations on the Effectiveness of Controls and Procedures***

In designing and evaluating our disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable, not absolute, assurance of achieving the desired control objectives. In addition, the design of disclosure controls and procedures must reflect the fact that there are resource constraints and that management is required to apply judgment in evaluating the benefits of possible controls and procedures relative to their costs. The design of any disclosure controls and procedures also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions.

### ***Changes in Internal Control over Financial Reporting***

There has been no change in our internal control over financial reporting (as defined in Rule 13a-15(f) under the Exchange Act) during our most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

**PART II - OTHER INFORMATION****Item 1. Legal Proceedings.**

We are not party to any material pending legal proceedings. From time to time, we may be involved in legal proceedings arising in the ordinary course of business.

**Item 1A. Risk Factors.**

There have been no material changes to the risk factors included in our Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2018.

**Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.**

None.

**Item 3. Defaults Upon Senior Securities.**

None.

**Item 4. Mine Safety Disclosures.**

Not applicable.

**Item 5. Other Information.**

None.

**Item 6. Exhibits.**

The exhibits filed or furnished as part of this Quarterly Report on Form 10-Q are set forth on the Exhibit Index, which Exhibit Index is incorporated herein by reference.

**EXHIBIT INDEX**

| Exhibit Number | Exhibit Description   | Incorporated by Reference |          |         | Filed Herewith |
|----------------|---|---------------------------|----------|---------|----------------|
|                |   | Form                      | File No. | Exhibit |                |
| 31.1           | <a href="#">Certification of Principal Executive Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a> |                           |          |         | X              |
| 31.2           | <a href="#">Certification of Principal Financial Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a> |                           |          |         | X              |
| 32.1*          | <a href="#">Certifications of Principal Executive Officer and Principal Financial Officer, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a>                |                           |          |         | X              |
| 101.INS        | XBRL Instance Document.   |                           |          |         | X              |
| 101.SCH        | XBRL Taxonomy Extension Schema Document.  |                           |          |         | X              |
| 101.CAL        | XBRL Taxonomy Extension Calculation Linkbase Document.  |                           |          |         | X              |

[Table of Contents](#)

|         |   |   |
|---------|---|---|
| 101.LAB | XBRL Taxonomy Extension Label Linkbase Document.        | X |
| 101.PRE | XBRL Taxonomy Extension Presentation Linkbase Document. | X |
| 101.DEF | XBRL Taxonomy Extension Definition Linkbase Document.   | X |

---

\* The certifications attached as Exhibit 32.1 that accompany this Quarterly Report pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, shall not be deemed “filed” by the registrant for purposes of Section 18 of the Exchange Act and are not to be incorporated by reference into any of the registrant’s filings under the Securities Act or the Exchange Act, irrespective of any general incorporation language contained in any such filing.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

MADRIGAL PHARMACEUTICALS, INC.

Date: November 6, 2018

By: /s/ Paul A. Friedman, M.D.

Paul A. Friedman, M.D.  
Chief Executive Officer  
(Principal Executive Officer)

Date: November 6, 2018

By: /s/ Marc R. Schneebaum

Marc R. Schneebaum  
Chief Financial Officer  
(Principal Financial and Accounting Officer)

**CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER PURSUANT TO  
EXCHANGE ACT RULES 13a-14(a) AND 15d-14(a)  
AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002**

I, Paul A. Friedman, M.D., certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of Madrigal Pharmaceuticals, Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
  - (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
  - (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
  - (c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
  - (d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
  - (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
  - (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

/s/ Paul A. Friedman, M.D.

Paul A. Friedman, M.D.

Chief Executive Officer and Chairman of the Board

(Principal Executive Officer)

Date: November 6, 2018



**CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER PURSUANT TO  
EXCHANGE ACT RULES 13a-14(a) AND 15d-14(a)  
AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002**

I, Marc R. Schneebaum, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of Madrigal Pharmaceuticals, Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
  - (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
  - (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
  - (c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
  - (d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
  - (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
  - (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

/s/ Marc R. Schneebaum

Marc R. Schneebaum

Senior Vice President and Chief Financial Officer

(Principal Financial Officer)

Date: November 6, 2018

**CERTIFICATIONS PURSUANT TO 18 U.S.C. SECTION 1350,  
AS ADOPTED PURSUANT TO SECTION 906  
OF THE SARBANES-OXLEY ACT OF 2002**

Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (Subsections (a) and (b) of Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. Section 1350)), each of the undersigned officers of Madrigal Pharmaceuticals, Inc., a Delaware corporation (the "Company"), does hereby certify, to such officer's knowledge, that:

The Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2018 (the "Form 10-Q") of the Company fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, and the information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: November 6, 2018

/s/ Paul A. Friedman, M.D.

Paul A. Friedman, M.D.

Chief Executive Officer and Chairman of the Board

(Principal Executive Officer)

Dated: November 6, 2018

/s/ Marc R. Schneebaum

Marc R. Schneebaum

Senior Vice President and Chief Financial Officer

(Principal Accounting and Financial Officer)

These certifications accompany the Form 10-Q, are not deemed filed with the Securities and Exchange Commission and are not to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form 10-Q), irrespective of any general incorporation language contained in such filing.